Aradigm Corporation announced that it has received patents for its Pulmaquin inhaled ciprofloxacin from the European and Australian patent offices. The European patent (EU Patent No. 2,079,443) is titled “Dual Action, Inhaled Formulations Providing Both an Immediate and Sustained Release Profile”; the Australian patent (AU2012211514) is titled “Concentrated, Inhalable Ciprofloxacin Formulation.”
Pulmaquin is already covered by multiple patents in the US and one in Japan.
Aradigm President and CEO Igor Gonda commented, “Long term patent protection of our lead product Pulmaquin is an important component of our corporate strategy. Our global efforts in this area are running in parallel with our Phase 3 clinical trials of Pulmaquin for non-cystic fibrosis bronchiectasis currently being conducted across five continents in 14 different countries.”
Grifols acquired an exclusive license for Pulmaquin and Lipoquin inhaled ciprofloxacin in May 2013 and Aradigm announced in June 2014 that it had received a $5 million milestone payment in association with the commencement of the ORBIT-3 clinical trial.
Read the Aradigm press release.
